



# PRIOR AUTHORIZATION REQUEST

## INSULIN PRODUCTS

### Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

### Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

### Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

**SECTION A:** Please note that supporting clinical documentation is required for **ALL PA requests**. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

1	Is the request an INITIAL or CONTINUATION of therapy?	
	<input type="checkbox"/> Initial (If checked, go to 7)	
	<input type="checkbox"/> Continuation (If checked, go to 2)	
2	Is the patient currently receiving the requested medication? [If no, skip to question 7.]	Yes      No

If you have any questions, call:  
1-888-258-8250

Version 06.2026

# PRIOR AUTHORIZATION REQUEST

- |   |  |     |    |
|---|--|-----|----|
| 3 | Has the patient been receiving medication samples for the requested medication?<br>[If yes, skip to question 7.]   | Yes | No |
| 4 | Does the patient have a previously approved prior authorization (PA) on file with the current plan?<br>[Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.]<br>[If no, skip to question 7.]   | Yes | No |
| 5 | Has the patient been established on therapy for at least 3 months?<br>[If no, skip to question 7.]   | Yes | No |
| 6 | Has documentation been submitted to confirm that the patient has had a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation.<br>[No further questions.]  | Yes | No |
| 7 | What is the patient's indication or diagnosis?<br><br><input type="checkbox"/> Diabetes mellitus (If checked, go to 8)<br><br><input type="checkbox"/> Other (If checked, no further questions)  |     |    |
| 8 | What is the requested medication?<br><br><input type="checkbox"/> Apidra (insulin glulisine) (If checked, go to 9)<br><input type="checkbox"/> Novolog (insulin aspart) (If checked, go to 10)<br><input type="checkbox"/> Fiasp (insulin aspart) (If checked, go to 10)<br><input type="checkbox"/> Kirsty (insulin aspart-xjhz) (If checked, go to 10)<br><input type="checkbox"/> Merilog (insulin aspart-szjj) (If checked, go to 10)<br><input type="checkbox"/> Humalog (insulin lispro) (If checked, go to 10)<br><input type="checkbox"/> Lyumjev (insulin lispro-aabc) (If checked, go to 10)<br><input type="checkbox"/> Humulin (insulin regular) (If checked, go to 10)<br><input type="checkbox"/> Humulin U-500 (insulin regular) (If checked, go to 11)<br><input type="checkbox"/> Toujeo (insulin glargine 300 U/mL) (If checked, go to 11)<br><input type="checkbox"/> Tresiba (insulin degludec) (If checked, go to 12) |     |    |

If you have any  
questions, call:  
1-888-258-8250

Version 06.2026

## PRIOR AUTHORIZATION REQUEST

Lantus (insulin glargine) (If checked, go to 12)

Awiqli (insulin icodec-abae) (If checked, go to 12)

Basaglar (insulin glargine) (If checked, go to 12)

Semglee (insulin glargine-yfgn) (If checked, go to 12)

Levemir (insulin detemir) (If checked, go to 12)

Novolin (insulin NPH) (If checked, go to 12)

9	Is the patient GREATER THAN 4 years of age? [If no, no further questions.]	Yes	No
10	Has documentation been submitted to confirm that the patient has tried and failed the following formulary rapid-acting insulin product: Admelog? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
11	Does the patient require a dose GREATER THAN 100 units per day of BASAL insulin (such as Insulin glargine-yfgn)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
12	Has documentation been submitted to confirm that the patient has tried and failed ALL of the following formulary long-acting insulin products: A) Insulin glargine-yfgn, B) Rezvoglar? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
13	Is the request for a generic formulation? [Note: If there is no generic formulation available for the requested insulin product, select 'Yes'.] [If yes, skip to question 15.]	Yes	No
14	Has the patient tried and failed the generic formulation? [If no, no further questions.]	Yes	No
15	Does the requested dose exceed FDA approved label dosing for the requested indication?	Yes	No

***Please document the diagnoses, symptoms, and/or any other information important to this review:***

**If you have any  
questions, call:  
1-888-258-8250**

Version 06.2026



# PRIOR AUTHORIZATION REQUEST

---

---

---

**SECTION B:** Physician Signature

---

PHYSICIAN SIGNATURE DATE

**FAX COMPLETED FORM TO: 1-833-896-0656**

**Disclaimer:** An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**Confidentiality:** The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call:  
1-888-258-8250

Version 06.2026